An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer.

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 9, 2016

Primary Completion Date

August 27, 2020

Study Completion Date

June 30, 2022

Conditions

Breast Cancer

Interventions

DRUG

Ribociclib

DRUG

T-DM1

DRUG

Trastuzumab

DRUG

Fulvestrant

Trial Locations (2)

Massacusetts General Hospital, Boston

Dana-Farber Cancer Institute, Boston